Compare NTLA & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | PGY |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2016 | 2021 |
| Metric | NTLA | PGY |
|---|---|---|
| Price | $12.72 | $22.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | $20.02 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 3.1M | 2.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 116.43 |
| EPS | N/A | ★ 0.77 |
| Revenue | $67,671,000.00 | ★ $1,301,360,000.00 |
| Revenue This Year | N/A | $14.27 |
| Revenue Next Year | $62.75 | $14.39 |
| P/E Ratio | ★ N/A | $29.88 |
| Revenue Growth | 16.92 | ★ 26.07 |
| 52 Week Low | $7.95 | $10.40 |
| 52 Week High | $28.24 | $44.99 |
| Indicator | NTLA | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 62.25 |
| Support Level | $12.55 | $20.44 |
| Resistance Level | $13.88 | $23.22 |
| Average True Range (ATR) | 0.66 | 1.15 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 53.28 | 83.78 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.